Search clinical trials for: Incretin analogues

Total 2060 results

Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years

Obesity | Metabolism and Nutrition Disorder

Germany
Steno Diabetes Center Copenhagen
University of Copenhagen; University Hospital, Gentofte, Copenhagen

Completed

Liraglutide in Type 1 Diabetes

Diabetes Mellitus, Type 1 | Overweight

Denmark
Bo Feldt-Rasmussen
Novo Nordisk A/S; The GCP unit at Copenhagen University Hospital

Withdrawn

The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure (LiRA2)

Kidney Failure, Chronic | Prediabetic State

Denmark
Vastra Gotaland Region
Novo Nordisk A/S

Completed

Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections

Type 2 Diabetes Mellitus

Sweden
Novo Nordisk A/S

Completed

Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

Diabetes Mellitus, Type 2 | Diabetes

Poland
University Hospital, Gentofte, Copenhagen
University of Copenhagen; Steno Diabetes Center Copenhagen

Completed

Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)

Maturity-onset Diabetes of the Young

Denmark
Cairo University

Unknown

Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy

Blood Loss

Egypt
Eli Lilly and Company

Recruiting

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

Obesity

United States
Biolingus
Chinese University of Hong Kong

Recruiting

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

Diabete Type 2

Hong Kong
Novo Nordisk A/S

Completed

GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan. (GOAL)

Diabetes Mellitus, Type 2

Japan
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) (SURMOUNT-CN)

Obesity | Overweight | Metabolism and Nutrition Disorder

China
Novo Nordisk A/S

Completed

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Obesity | Metabolism and Nutrition Disorder

France, United States, Turkey, Italy, Australia, New Zealand, Canada, Netherlands
Eli Lilly and Company

Completed

A Study of LY3537021 in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Type 2 Diabetes

United States
MedImmune LLC

Completed

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

Netherlands, Sweden
Novo Nordisk A/S

Completed

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Russian Federation, Puerto Rico, United Arab Emirates, Brazil
Hvidovre University Hospital
Steno Diabetes Center Copenhagen

Completed

The Lira Pump Trial

Type 1 Diabetes

Denmark
Cedars-Sinai Medical Center

Withdrawn

Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

Type 2 Diabetes

United States
Centre Hospitalier Universitaire Dijon

Terminated

Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes (GLP1 et Goût)

Overweight | Type 2 Diabetes

France
Imperial College London
King's College Hospital NHS Trust; University of Oxford; University of Southampton and other collaborators

Unknown

Evaluating Liraglutide in Alzheimer's Disease (ELAD)

Alzheimer's Disease

United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Russian Federation, United Kingdom, France, Ukraine
Novo Nordisk A/S

Completed

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Obesity | Metabolism and Nutrition Disorder

United States
GlaxoSmithKline

Withdrawn

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Profil Institut für Stoffwechselforschung GmbH

Terminated

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Obesity | Metabolism and Nutrition Disorder | Obstructive Sleep Apnoea

United States, Canada
Novo Nordisk A/S

Completed

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Obesity | Metabolism and Nutrition Disorder

United States, Canada
Beth Israel Deaconess Medical Center

Completed

Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

Diabetes | Weight Loss | Hunger | Effects of Liraglutide Administration on Brain Activity

United States
Novo Nordisk A/S

Completed

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (ADJUNCT ONE™)

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Poland, United Kingdom, France, Sweden, Netherlands, Finland, Belgium, Ireland, Germany, Canada, Russian Federation, Australia, Norway, Argentina, Ukraine
Novo Nordisk A/S

Completed

To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo

Healthy | Diabetes

China
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers

Healthy | Diabetes

Japan
Steno Diabetes Center Copenhagen
Novo Nordisk A/S

Completed

Antiproteinuric Effects of Liraglutide Treatment (LIRALBU)

Diabetic Kidney Disease

Denmark
King's College London
Guy's and St Thomas' NHS Foundation Trust

Completed

Liraglutide to Improve corONary Haemodynamics During Exercise streSS (LIONESS)

Coronary Heart Disease | Chronic Stable Angina | Ischaemic Heart Disease

United Kingdom
Peter Rossing
Novo Nordisk A/S

Completed

Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes (Liratime)

Type 2 Diabetes

Denmark
Pennington Biomedical Research Center

Active, not recruiting

Role Of Metabolic Adaptation In Weight Regain (EXPEND-FU)

Obesity | Weight Loss | Weight Gain

United States
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

Type 2 Diabetes

China
Unidad de Cirugia Bariatrica Hospital Civil Dr....

Completed

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

Weight Loss | Obesity, Morbid | Bariatric Surgery Candidate

Mexico
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease (SURMOUNT-J)

Obesity

Japan
Eli Lilly and Company

Completed

A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes

Healthy

United States
Eli Lilly and Company

Completed

A Study of Tirzepatide in Participants With Impaired Liver Function

Hepatic Insufficiency

United States
University of Leeds

Completed

Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes (Lean-DM)

Diabetes Mellitus, Type 2

United Kingdom
Novo Nordisk A/S

Withdrawn

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia (GLIDE)

Diabetes Mellitus, Type 2
Stefano Rizza

Completed

Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira) (XETD2)

Type2 Diabetes

Italy
Rigshospitalet, Denmark
Novo Nordisk A/S; Slagelse Hospital

Completed

Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients

Diabetes Mellitus Type 2 | Diastolic Dysfunction | Myocardial Perfusion | Cardiac MRI

Denmark
Signe Torekov
Karolinska Institutet; University of Oxford; Hvidovre University Hospital

Unknown

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet (S-LITE)

Obesity

Denmark
Novo Nordisk A/S

Completed

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Israel, Italy, Mexico, Puerto Rico, Russian Federation, Spain, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Taiwan, Finland, Norway, Serbia, South Africa, Turkey, Canada, France, Germany, Korea, Republic of and more
Eli Lilly and Company

Completed

A Study of LY3025876 in Participants With Diabetes

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

Obesity | Metabolism and Nutrition Disorder

Denmark

Search clinical trials for: Incretin analogues

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations